Friday, July 4, 2025 7/4/2025

Novel sequencing by synthesis chemistry to further reduce the cost of nucleic acid sequencing

Award Number: R44HG011060
ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2020
PERIOD OF PERFORMANCE END DATE: 01/31/2022

Group Awards By:

View Award Description

Novel sequencing by synthesis chemistry to further reduce the cost of nucleic acid sequencing - PROJECT SUMMARY Ultima Genomics, Inc. proposes to develop a novel sequencing-by-synthesis (SBS) chemistry that will further leverage the strengths of the company's high-throughput sequencing system. The new technology will further reduce cost compared with state-of-the-art commercial technologies and will particularly benefit DNA sequencing applications that are cost constrained, such as sequencing large populations, generating methylation and transcriptome profiles for millions of single cells, and enabling liquid biopsy applications. Target customers include genome centers, CROs, research labs, and clinical labs. The company is pioneering a series of inter-related innovations that mutually reinforce one another in a virtuous circle to achieve much lower cost. The first generation of this platform – which is currently under development and will soon be seeded to select beta test sites – substantially advances the state of the art, but does not exploit the full potential of the innovations. In the proposed Direct to Phase 2 project, the company will design, develop, and optimize a new chemistry that unlocks the full potential of the platform; port the new chemistry to the existing hardware platform while maintaining highly competitive specifications for accuracy, read length, and time to answer; demonstrate the throughput improvements that will further lower overall costs; and rigorously validate performance across these and other metrics. By dramatically reducing sequencing cost, Ultima Genomics' technology will directly impact a wide range of scientific capabilities with direct relevance for public health, including characterization of tumors, detection of early stage cancers through blood test, and personalized/precision medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	000	2	5/3/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $617,578 )
2021	2021	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	001	2	4/1/2021	NON-COMPETING CONTINUATION	$617,578
2021	2020	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	000	1	1/15/2021	NEW	$0
														Subtotal = $617,578

Issue Date FY: 2020 ( Subtotal = $1,382,286 )
2020	2020	ULTIMA GENOMICS, INC.	7979 GATEWAY BLVD STE 101	NEWARK	CA	94560	ALAMEDA	USA	Human Genome Research	000	1	4/27/2020	NEW	$1,382,286
														Subtotal = $1,382,286

Grand Total All Awards = $1,999,864

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel sequencing by synthesis chemistry to further reduce the cost of nucleic acid sequencing

Award Number: R44HG011060

ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2020

PERIOD OF PERFORMANCE END DATE: 01/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer